Query: High-throughput calcium transient assay development in aged human primary myotubes screening diverse small-molecule libraries for restoration of impaired calcium signaling and contractile function: methodological optimization, validation metrics (Z’-factor, signal-to-noise), compound handling, imaging modalities, assay reproducibility studies

High-throughput calcium transient assay development in aged human primary myotubes requires rigorous methodological optimization to reliably assess restoration of impaired calcium signaling and contractile function. One fundamental aspect is the establishment of a robust platform that integrates both contractility and calcium imaging. For example, engineered muscle constructs mounted between a fixed anchor and a force transducer, as detailed for contractile force measurements, provide quantitative outputs such as twitch and tetanus force amplitudes along with kinetic parameters that inform on functional maturity (juhas2016designevaluationand pages 9-10).

Validation metrics such as the Z’-factor and signal-to-noise ratio are essential in this context to ensure assay quality and reproducibility. Although not all excerpts explicitly mention these parameters, multiple studies underscore that rigorous statistical validation—including calculations of Z’-factor and normalization against well-defined positive and negative controls—is critical for high-throughput screening (rebbeck2020ryr1targeteddrugdiscovery pages 12-12, rebbeck2020ryr1targeteddrugdiscovery pages 7-9). Ensuring that each plate yields Z’-factors within acceptable thresholds leads to confidence in the assay's dynamic range and its ability to detect small-molecule effects on calcium transients.

Compound handling is another key methodological component. The use of precise and automated compound dispensing systems, such as acoustic dispensers that deliver nanoliter volumes of highly concentrated stock solutions (e.g., 5 nL of 10 mM), ensures consistent compound dosing and minimizes variability (rebbeck2020ryr1targeteddrugdiscovery pages 5-6). Such precision is particularly important when screening diverse libraries, as maintaining compound integrity and proper storage conditions (i.e., -20°C for assay plates) minimizes degradation and cross-contamination, thereby enhancing assay reproducibility.

In terms of imaging modalities, the integration of fluorescence-based techniques is imperative. Calcium-sensitive dyes like Fura-2, Rhod-2, or genetically encoded indicators (e.g., GCaMP) have been used to capture intracellular calcium transients in real time (juhas2016designevaluationand pages 9-10, mosqueira2018diseasemodelinghypertrophic pages 56-58). Advanced optical mapping, using state-of-the-art cameras coupled with high-content imaging systems, allows rapid acquisition of high-resolution spatial and temporal data. Furthermore, fluorescence lifetime (FLT)-based Förster Resonance Energy Transfer (FRET) assays provide additional precision by directly reflecting changes in protein–protein interactions that underlie the modulation of calcium release channels (rebbeck2020ryr1targeteddrugdiscovery pages 1-2).

Imaging platforms often involve automated recording systems integrated with custom software for real-time analysis, which is vital for high-throughput settings. High-content imaging systems, as exemplified by protocols where imaging is performed in 384-well plate formats, facilitate both qualitative and quantitative assessments of calcium transients and contractile responses (murphy2021pgc1ppardrivecardiomyocyte pages 10-11). Such systems are also optimized to control for exposure, background fluorescence, and signal saturation, collectively ensuring high signal-to-noise ratios.

Assay reproducibility studies incorporate multiple biological and technical replicates, appropriate statistical analyses (typically using two-sided Student’s t-tests or ANOVA with Tukey’s post hoc tests), and validation using both genetic and pharmacological tools (shu2019developmentofa pages 10-12, shu2019developmentofa pages 7-8). The use of isogenic controls and dose-response curves further strengthens the translational relevance and reliability of the assay, especially when adapted for aged human primary myotubes where functional responses may be diminished.

Collectively, these methodological components—optimization of contractile force measurements and calcium imaging, rigorous validation via Z’-factor and signal-to-noise ratios, precision in compound handling, and high-resolution imaging modalities—are critical for developing a state-of-the-art high-throughput screening platform capable of restoring impaired calcium signaling and contractile function in aged human primary myotubes (juhas2016designevaluationand pages 9-10, mosqueira2018diseasemodelinghypertrophic pages 56-58, rebbeck2020ryr1targeteddrugdiscovery pages 1-2).

References:
1. (juhas2016designevaluationand pages 9-10): Mark Juhas, Jean Ye, and Nenad Bursac. Design, evaluation, and application of engineered skeletal muscle. Methods, 99:81-90, Apr 2016. URL: https://doi.org/10.1016/j.ymeth.2015.10.002, doi:10.1016/j.ymeth.2015.10.002. This article has 74 citations and is from a peer-reviewed journal.

2. (mosqueira2018diseasemodelinghypertrophic pages 56-58): D Mosqueira. Disease modeling hypertrophic cardiomyopathy using crispr/cas9 genome editing technology in human pluripotent stem cell-derived cardiomyocytes. Unknown journal, 2018.

3. (rebbeck2020ryr1targeteddrugdiscovery pages 1-2): Robyn T. Rebbeck, Daniel P. Singh, Kevyn A. Janicek, Donald M. Bers, David D. Thomas, Bradley S. Launikonis, and Razvan L. Cornea. Ryr1-targeted drug discovery pipeline integrating fret-based high-throughput screening and human myofiber dynamic ca2+ assays. Scientific Reports, Feb 2020. URL: https://doi.org/10.1038/s41598-020-58461-1, doi:10.1038/s41598-020-58461-1. This article has 37 citations and is from a poor quality or predatory journal.

4. (rebbeck2020ryr1targeteddrugdiscovery pages 12-12): Robyn T. Rebbeck, Daniel P. Singh, Kevyn A. Janicek, Donald M. Bers, David D. Thomas, Bradley S. Launikonis, and Razvan L. Cornea. Ryr1-targeted drug discovery pipeline integrating fret-based high-throughput screening and human myofiber dynamic ca2+ assays. Scientific Reports, Feb 2020. URL: https://doi.org/10.1038/s41598-020-58461-1, doi:10.1038/s41598-020-58461-1. This article has 37 citations and is from a poor quality or predatory journal.

5. (shu2019developmentofa pages 10-12): Cynthia Shu, Ariana N. Kaxon-Rupp, Judd R. Collado, Robert Damoiseaux, and Rachelle H. Crosbie. Development of a high-throughput screen to identify small molecule enhancers of sarcospan for the treatment of duchenne muscular dystrophy. Skeletal Muscle, Dec 2019. URL: https://doi.org/10.1186/s13395-019-0218-x, doi:10.1186/s13395-019-0218-x. This article has 12 citations and is from a peer-reviewed journal.

6. (murphy2021pgc1ppardrivecardiomyocyte pages 10-11): Sean A. Murphy, Matthew Miyamoto, Anaïs Kervadec, Suraj Kannan, Emmanouil Tampakakis, Sandeep Kambhampati, Brian Leei Lin, Sam Paek, Peter Andersen, Dong-Ik Lee, Renjun Zhu, Steven S. An, David A. Kass, Hideki Uosaki, Alexandre R. Colas, and Chulan Kwon. Pgc1/ppar drive cardiomyocyte maturation at single cell level via yap1 and sf3b2. Nature Communications, Mar 2021. URL: https://doi.org/10.1038/s41467-021-21957-z, doi:10.1038/s41467-021-21957-z. This article has 78 citations and is from a highest quality peer-reviewed journal.

7. (rebbeck2020ryr1targeteddrugdiscovery pages 5-6): Robyn T. Rebbeck, Daniel P. Singh, Kevyn A. Janicek, Donald M. Bers, David D. Thomas, Bradley S. Launikonis, and Razvan L. Cornea. Ryr1-targeted drug discovery pipeline integrating fret-based high-throughput screening and human myofiber dynamic ca2+ assays. Scientific Reports, Feb 2020. URL: https://doi.org/10.1038/s41598-020-58461-1, doi:10.1038/s41598-020-58461-1. This article has 37 citations and is from a poor quality or predatory journal.

8. (rebbeck2020ryr1targeteddrugdiscovery pages 7-9): Robyn T. Rebbeck, Daniel P. Singh, Kevyn A. Janicek, Donald M. Bers, David D. Thomas, Bradley S. Launikonis, and Razvan L. Cornea. Ryr1-targeted drug discovery pipeline integrating fret-based high-throughput screening and human myofiber dynamic ca2+ assays. Scientific Reports, Feb 2020. URL: https://doi.org/10.1038/s41598-020-58461-1, doi:10.1038/s41598-020-58461-1. This article has 37 citations and is from a poor quality or predatory journal.

9. (shu2019developmentofa pages 7-8): Cynthia Shu, Ariana N. Kaxon-Rupp, Judd R. Collado, Robert Damoiseaux, and Rachelle H. Crosbie. Development of a high-throughput screen to identify small molecule enhancers of sarcospan for the treatment of duchenne muscular dystrophy. Skeletal Muscle, Dec 2019. URL: https://doi.org/10.1186/s13395-019-0218-x, doi:10.1186/s13395-019-0218-x. This article has 12 citations and is from a peer-reviewed journal.
